CLDN18.2靶點成藥，十年的等待或終將成真

最長OS，為胃癌患者的“多數(shù)派”帶來福音

國內(nèi)外指南推薦的胃癌一線治療方案

注：FOLFOX為亞葉酸鈣+卡培他濱/5-FU+奧利沙鉑，XELOX為奧利沙鉑+卡培他濱，PF為順鉑+5-FU，DCF為甲地孕酮+5-FU+順鉑+多西紫杉醇，mDCF為5-FU+順鉑+多西紫杉醇

HER2陰性晚期胃癌一線治療藥物III期數(shù)據(jù)

HER2陰性晚期胃癌一線治療藥物亞洲人群療效

總結(jié)

[1] Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2? locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study. ASCO GI 2023.

[2] Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011;481(2):83-92.

[3] FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609-619.

[4] Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol. 2019;49(9):870-876.

[5] Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189-1198.

[6] Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624-7634.

[7] Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J Pers Med. 2021;11(11):1095. Published 2021 Oct 26.

[8] Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer. Chin J Cancer Res. 2020;32(2):263-270.

[9] Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas. Journal of Clinical Oncology. 2013.

[10] DOI: 10.1200/JCO.2016.34.18_suppl.LBA4001 Journal of Clinical Oncology 34, no. 18_suppl.

[11] Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.

[12] https://gco.iarc.fr/today/home. Cancer fact sheets. Digestive organs. Stomach(C16).

[13] AJCC TNM分期8.0版胃癌.

[14] Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Arch. 2019;475(5):563-571.

[15] HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma:Guideline From the College of American Pathologists,American Society for Clinical Pathology,and the American Society of Clinical Oncology.J Clin Oncol.2017 Feb;35(4):446-464.

[16] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571-1580.

[17] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for

advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma

(GC/GEJC/EAC): 3-year follow-up from CheckMate 649. ASCO GI 2023.

[18] 《NCCN臨床實踐指南：胃癌2022版》.

[19] 《CSCO胃癌診療指南2022版》.

[20] 默沙東ESMO Virtual Plenary新聞稿.

[21] LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study.ESMO 2021(32).

[22] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction

adenocarcinoma (GC/GEJC). ASCO GI 2023.

[23] Claudin18.2和PD-L1在中國胃腺癌和食管胃結(jié)合部腺癌中的表達. SITC 37th Annual Meeting 2022.

[24] https://clinicaltrials.gov/ct2/show/NCT03505320.

[25] Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol. 2021;39(9):966-977.

聲明：本文系藥方舟轉(zhuǎn)載內(nèi)容，版權(quán)歸原作者所有，轉(zhuǎn)載目的在于傳遞更多信息，并不代表本平臺觀點。如涉及作品內(nèi)容、版權(quán)和其它問題，請與本網(wǎng)站留言聯(lián)系，我們將在第一時間刪除內(nèi)容